Sergio Carbonara

Dr. Sergio Carbonara

ASL BT, Andria, Puglia, Italy

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
AVAntonio Vena
Antonio Vena
Daniele Roberto GiacobbeDaniele Roberto Giacobbe
Daniele Roberto Giacobbe
NCNadia Castaldo
Nadia Castaldo
ACANNA MARIA CATTELAN
ANNA MARIA CATTELAN
CMCristina Mussini
Cristina Mussini
FGfor the Ceftabuse Study Group
for the Ceftabuse Study Group
Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram−negative bacteria (GNB) other than carbapenem-resistant Enterobacterales (CRE) is very limited. Methods: We carried out a retrospective multicenter study of patients hospitalized in 13 Italian hospitals who received ≥72 h of ceftazidime-avibactam for GNB other than CRE to assess the rates of clinical success, resistance development, and occurrence of adverse events. Results: Ceftazidime-avibactam was used to treat 41 patients with GNB infections other than CRE. Median age was 62 years and 68% of them were male. The main causative agents were P. aeruginosa (33/41; 80.5%) and extended spectrum beta lactamase (ESBL)-producing Enterobacterales (4/41, 9.8%). Four patients had polymicrobial infections. All strains were susceptible to ceftazidime-avibactam. The most common primary infection was nosocomial pneumonia (n = 20; 48.8%), primary bacteremia (n = 7; 17.1%), intra-abdominal infection (n = 4; 9.8%), and bone infection (n = 4; 9.8%). Ceftazidime-avibactam was mainly administered as a combination treatment (n = 33; 80.5%) and the median length of therapy was 13 days. Clinical success at the end of the follow-up period was 90.5%, and the only risk factor for treatment failure at multivariate analysis was receiving continuous renal replacement therapy during ceftazidime-avibactam. There was no association between clinical failures and type of primary infection, microbiological isolates, and monotherapy with ceftazidime-avibactam. Only one patient experienced recurrent infection 5 days after the end of treatment. Development of resistance to ceftazidime-avibactam was not detected in any case during the whole follow-up period. No adverse events related to ceftazidime-avibactam were observed in the study population. Conclusions: Ceftazidime-avibactam may be a valuable therapeutic option for serious infections due to GNB other than CRE.

12 July 2000 in JAMA
Verified
Journal Article
Closed access
PFPhil B. Fontanarosa
Phil B. Fontanarosa
SBSergio Babudieri
Sergio Babudieri
AAAntonio Aceti
Antonio Aceti
GDGian Piero D'OFfizi
Gian Piero D'OFfizi
SCSergio Carbonara
Sergio Carbonara
GSGiulio Starnini
Giulio Starnini

1 December 2012
Verified
Journal Article
Closed access
ESEvangelista Sagnelli
Evangelista Sagnelli
GSG Starnini
G Starnini
Caterina SagnelliCaterina Sagnelli
Caterina Sagnelli
RMR Monarca
R Monarca
GZG Zumbo
G Zumbo
SGSimspe Group
Simspe Group

30 October 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
Francesco Di GennaroFrancesco Di Gennaro
Francesco Di Gennaro
SCSergio Cotugno
Sergio Cotugno
GGGiacomo Guido
Giacomo Guido
FCFrancesco Cavallin
Francesco Cavallin
MPMariantonietta Pisaturo
Mariantonietta Pisaturo
ASAnnalisa Saracino
Annalisa Saracino
Tuberculosis (TB) remains a Global Health challenge, with diagnostic delays contributing significantly to its spread. This study investigates the differences in diagnostic delays between native and migrant TB patients in Italy, examining patient-related diagnostic delay (PDD), health system-related diagnostic delay (HDD), and total diagnostic delay (TDD). We conducted a retrospective, multicenter, cross-sectional study of TB cases in 10 Italian hospitals from 2018 to 2023. We compared PDD, HDD, and TDD between native and migrant populations. Socio-demographic data and clinical histories were analyzed to identify factors contributing to diagnostic delays. We included 669 TB patients (390 migrants and 279 natives). Migrants experienced significantly longer PDD (median 90 vs 10 days, P < 0.0001) but shorter HDD (median 5 vs 40 days, P < 0.0001) compared to natives, resulting in a longer TDD (median 96 vs 65 days, P < 0.0001). Furthermore, migrants had higher Timika scores, longer sputum conversion times, and were more frequently lost to follow-up. Migrants face longer PDD, emphasizing substantial barriers to healthcare access. Natives experience longer HDD, reflecting neglect of TB in low-endemic regions. Future research should focus on the impact of social determinants and training for healthcare providers on TB diagnosis and develop strategies to reduce diagnostic delays.

1 June 2005 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
SCSergio Carbonara
Sergio Carbonara
SBSergio Babudieri
Sergio Babudieri
BLB. Longo
B. Longo
GSG. Starnini
G. Starnini
RMR. Monarca
R. Monarca
GPGlip (Gruppo di Lavoro Infettivologi Penitenziari)
Glip (Gruppo di Lavoro Infettivologi Penitenziari)
Prisons represent a crucial setting for tuberculosis control. Currently, there is scarce information concerningMycobacterium tuberculosis(MT) infection in European prisons, and no data are available for Italy. This study aims to describe the prevalence and correlates of MT infection in an Italian prison population.In this multicentre cross-sectional study, 1,247 inmates from nine prisons were recruited and asked to undergo questioning regarding socio-economic and demographic variables, tuberculin skin testing (TST), chest radiographs and testing for HIV, hepatitis B and hepatitis C virus infection.TST was positive in 17.9% of the 448 evaluable subjects. With multivariate logistic regression (performed among male inmates), MT infection was correlated with age (adjusted odds ratio (OR) 4.12 for inmates aged 31–40 yrs; 3.78 for those aged >40 yrs), being foreign-born (OR = 4.9), education ≤5 yrs (OR = 1.88) and length of detention (increased risk per yr: 11%).As with elsewhere in the world, the prison system in Italy features a population with an increased rate ofMycobacterium tuberculosisinfection and at-risk rate forMycobacterium tuberculosistransmission. Improved tuberculosis surveillance and control measures are deemed necessary in correctional facilities nationwide, especially for subjects with the above risk factors and those who are HIV infected, in whom the tuberculin skin testing can be misleading. The screening of entrants is particularly important to avoid undiagnosed smear-positive tuberculosis cases.

1 November 2001 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
PMPaolo Maggi
Paolo Maggi
ALAngela Maria Vittoria Larocca
Angela Maria Vittoria Larocca
NLNicoletta Ladisa
Nicoletta Ladisa
SCSergio Carbonara
Sergio Carbonara
OBOlga Brandonisio
Olga Brandonisio
GPGiuseppe Pastore
Giuseppe Pastore
Sir—Opportunistic parasitic infections of the gastrointestinal tract frequently occur in patients with AIDS. In previous reports [1–3], we have described the epidemiology and clinical characteristics of cryptosporidiosis, microsporidiosis, and isosporiasis among patients with AIDS in our geographic region. However, during the last 3 years, the incidences of these diseases have sharply decreased, mainly because of the introduction of highly active antiretroviral therapy (HAART). Immediately after the introduction of this potent combination therapy, we observed its positive effect on the clearance of parasites in patients with cryptosporidiosis or microsporidiosis [4] who were being treated with antiprotozoal drugs. Currently, these diseases are rarely observed in our center. We describe 5 cases of opportunistic enteric infection (1 case of isosporiasis and 4 cases of cryptosporidiosis) in patients who demonstrated a poor virological and immunological response to HAART.